May 30 |
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
|
May 26 |
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week
|
May 14 |
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
|
May 9 |
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
|
May 7 |
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
|
May 7 |
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
|
May 3 |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
|
May 2 |
Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)
|
May 2 |
Aurinia Pharmaceuticals Inc. (AUPH) Q1 2024 Earnings Call Transcript
|
May 2 |
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
|